Allianz Asset Management GmbH Has $172.52 Million Stock Position in Tenet Healthcare Corporation $THC

Allianz Asset Management GmbH lifted its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 78.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 868,134 shares of the company’s stock after acquiring an additional 380,632 shares during the period. Allianz Asset Management GmbH’s holdings in Tenet Healthcare were worth $172,516,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of THC. Triumph Capital Management bought a new position in shares of Tenet Healthcare in the third quarter worth $25,000. Activest Wealth Management bought a new position in shares of Tenet Healthcare in the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new position in shares of Tenet Healthcare in the fourth quarter worth $29,000. Canada Pension Plan Investment Board bought a new position in shares of Tenet Healthcare in the second quarter worth $35,000. Finally, Geneos Wealth Management Inc. increased its position in shares of Tenet Healthcare by 50.9% in the second quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock worth $46,000 after purchasing an additional 89 shares during the period. Institutional investors own 95.44% of the company’s stock.

Tenet Healthcare Price Performance

Tenet Healthcare stock opened at $166.57 on Wednesday. The stock’s 50 day moving average is $185.02 and its 200 day moving average is $200.40. The company has a debt-to-equity ratio of 1.96, a current ratio of 1.36 and a quick ratio of 1.30. The firm has a market cap of $14.35 billion, a P/E ratio of 8.66, a P/E/G ratio of 1.34 and a beta of 1.28. Tenet Healthcare Corporation has a one year low of $146.60 and a one year high of $247.21.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings data on Thursday, April 30th. The company reported $4.82 EPS for the quarter, topping analysts’ consensus estimates of $4.21 by $0.61. The company had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.39 billion. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $4.36 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, research analysts expect that Tenet Healthcare Corporation will post 17.61 EPS for the current year.

Insider Activity at Tenet Healthcare

In other Tenet Healthcare news, Director J Robert Kerrey sold 5,638 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the transaction, the director directly owned 16,804 shares of the company’s stock, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nadja West sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total value of $532,050.00. Following the completion of the transaction, the director directly owned 24,805 shares in the company, valued at approximately $4,399,166.75. This trade represents a 10.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.97% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on THC shares. Mizuho lifted their target price on Tenet Healthcare from $235.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Wells Fargo & Company decreased their target price on Tenet Healthcare from $265.00 to $213.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. UBS Group lifted their target price on Tenet Healthcare from $260.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Guggenheim decreased their target price on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings cut Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 2nd. Eighteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $244.16.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.